<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02728492</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-13-NSCLC/OVA-7-QUI-1B</org_study_id>
    <nct_id>NCT02728492</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy</brief_title>
  <official_title>Open-label Multicenter Multiple Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Gemcitabine + Cisplatin Chemotherapy (Second Line for Patients With Non-small Cell Lung Cancer) or Paclitaxel + Carboplatin Chemotherapy (Second Line for Patients With Non-small-cell Lung Cancer, Second and Subsequent Lines for Patients With Epithelial Ovarian Cancer)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NewVac LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceutica N.V., Belgium</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NewVac LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Quisinostat besides its own efficacy, which can potentially lead to better results of
      polychemotherapy and increase the mean time to progression, it may be demonstrated that
      Quisinostat leads to sustained tumor sensitivity to platinum drugs. In this study safety and
      tolerability of multiple administrations of Quisinostat in doses ranging from 8 mg to 12 mg
      combined with standard backbone chemotherapy in patients with non-small cell lung cancer
      (second line) and ovarian cancer (second and subsequent lines) will be investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It was proven that Quisinostat increases HDAC1-inhibited E-cadherin expression (at the low
      concentrations of 30 nM) which increases susceptibility to epidermal growth factor inhibitors
      in case of non-small-cell lung cancer and stops proliferation of paclitaxel-resistant cells.
      Thus, besides its own efficacy, which can potentially lead to better results of
      polychemotherapy and increase the mean time to progression, it may be demonstrated that
      Quisinostat leads to sustained tumor sensitivity to platinum drugs and possibly to
      resensitiztion in case of acquired or primary resistance.

      The main objective of the study is to evaluate the safety and tolerability of Quisinostat in
      multiple ascending doses and establish its maximum tolerated dose (MTD), administered in
      combination with standard backbone chemotherapy, as follows: Gemcitabine + Cisplatin in
      patients with non-small-cell lung cancer (second line) and Paclitaxel + Carboplatin in
      patients with non-small-cell lung cancer (second line) and in patients with ovarian cancer
      (second and subsequent lines). MTD is defined as maximum dose at which DLT occurs in no more
      than 1 patient of 6.

      Secondary objectives are:

      • Study of pharmacokinetics (PK) of multiple dosing of Quisinostat administered in
      combination with chemotherapy, as follows: Gemcitabine + Cisplatin in patients with
      non-small-cell lung cancer (second line) and Paclitaxel + Carboplatin in patients with
      non-small-cell lung cancer (second line) and in patients with ovarian cancer (second and
      subsequent lines) Preliminary estimation of possible effect of the drug, added to
      chemotherapy, on tumor growth.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability of Quisinostat based on number of patients with treatment -related AEs assessed by CTCAE v4.0, number of patients with abnormal laboratory values and instrumental tests (ECG) that are related to treatment</measure>
    <time_frame>22 weeks</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Peak Plasma Concentration (Cmax) of Quisinostat</measure>
    <time_frame>Day 1, Day 7</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the Quisinostat plasma concentration versus time curve (AUC)</measure>
    <time_frame>Day 1, Day 7</time_frame>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Epithelial Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Quisinostat 8 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quisinostat 8 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quisinostat 10 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quisinostat 10 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quisinostat 12 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quisinostat 12 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quisinostat 8 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quisinostat 8 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quisinostat 10 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quisinostat 10 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quisinostat 12 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quisinostat 12 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quisinostat 12 mg &amp; Gemcitabine 1250 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quisinostat 12 mg capsule every other day and Gemcitabine 1250 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quisinostat</intervention_name>
    <arm_group_label>Quisinostat 8 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_label>Quisinostat 10 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_label>Quisinostat 12 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_label>Quisinostat 8 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 10 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 12 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 12 mg &amp; Gemcitabine 1250 mg/m2 &amp; Cisplatin</arm_group_label>
    <other_name>JNJ-26481585</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Quisinostat 8 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_label>Quisinostat 10 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_label>Quisinostat 12 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Quisinostat 8 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_label>Quisinostat 10 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_label>Quisinostat 12 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Quisinostat 8 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 10 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 12 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 12 mg &amp; Gemcitabine 1250 mg/m2 &amp; Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Quisinostat 8 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 10 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 12 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 12 mg &amp; Gemcitabine 1250 mg/m2 &amp; Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General criteria for the inclusion of patients with non-small cell lung cancer (NSCLC) and
        ovarian cancer (OC):

          1. Signed patient's information sheet and informed consent form to participate in the
             study

          2. Age 18 and older

          3. The value of left ventricular ejection fraction, as determined by echocardiography
             data, more than 50%

          4. Patient's ability to carry out visits and study procedures and to comply with the
             protocol

          5. Requirements to laboratory parameters determined below:

             Complete blood count: Absolute neutrophil count:

             Platelets:

             Haemoglobin: ≥ 1500/mm3 (1.5 x 109 cells/l)

               -  100 000/mm3 (100 x 109 cells/l)

               -  9.0 g/dl

             Liver function: Total bilirubin:

             aspartate aminotransferase (AST) and alanine aminotransferase (ALT): ≤ 1.5-fold of the
             upper limit of normal (ULN)

             ≤ 2.5--fold of ULN or ≤ 5.0-fold of ULN in case of metastases in liver Kidney
             function: GRF (by Cockcroft-Gault equation) &gt; 50 ml/min

          6. The expected survival time not less than 6 months

          7. Women and men of childbearing potential (not sterile or in menopause less than 2
             years) must be practicing an effective method of birth control starting from the
             screening period, during the study and 6 months after the last administration of the
             investigational product. Effective methods include use a condom or diaphragm (barrier
             method) with spermicide.

          8. Functional status of the patient according to the ECOG 0 - 2 Special criteria for
             patients with NSCLC

          9. Histologically or cytologically confirmed diagnosis of non-resectable non-small-cell
             lung cancer

         10. The progression of lung cancer after a maximum of one line of systemic anticancer
             therapy (adjuvant chemotherapy will be considered first-line therapy if the time from
             the moment of its completion until disease progression was less than 6 months)

         11. No history of treatment with Gemcitabine if the patient is planned for inclusion in
             the group of chemotherapy with Cisplatin and Gemcitabine, or Paclitaxel if the patient
             is planned for inclusion in the group of Carboplatin and Paclitaxel.

         12. Vital capacity of lung by spirometry data is more than 50% of normal at screening

             Special inclusion criteria for patients with ovarian cancer

         13. Histologically confirmed diagnosis of ovarian cancer.

         14. Progression after no more than three modes of anticancer drug therapy for ovarian
             cancer.

        Exclusion Criteria:

          1. Indications for X-ray therapy or chemoradiation therapy at the time of inclusion,
             regardless of the treated area;

          2. Presence of clinical and/or radiological signs of metastases in the brain and
             meningeal structures (CNS);

          3. Previous therapy with HDAC inhibitors

          4. Any contraindications to the chemotherapy with Gemcitabine + Cisplatin or Paclitaxel +
             Carboplatin (in patients with lung cancer); contraindications to chemotherapy
             according to the standard chemotherapy combination scheme Paclitaxel + Carboplatin (in
             female patients with ovarian cancer);

          5. Any contraindications to administration of glucocorticosteroids, antihistamine drugs,
             serotonin 5-HT3 receptor antagonists, aprepitant;

          6. Any contraindications to forced rehydration and/or administration of forced diuresis
             (in case of lung cancer);

          7. Conditions that require continuous use of oral anticoagulants, or clinically
             significant changes in blood coagulation parameters at screening (INR &gt; 1.5, aPTT&gt; 1.5
             х ULN)

          8. Conditions that require admission of prohibited drugs, or impossibility to replace
             those with allowed drugs in the study

          9. Current infection or other systemic conditions constituting a contraindication to the
             intended chemotherapy;

         10. Diseases of the digestive system which may infringe absorption of the investigational
             product (Crohn's disease, nonspecific ulcerative colitis, irritable bowel syndrome)

         11. Clinically significant cardiovascular diseases including:

               -  Myocardial infarction within 12 months before screening

               -  Unstable angina within 12 months before screening

               -  Congestive heart failure Class III or IV according to the New York Heart
                  Association criteria (NYHA)

               -  Clinically significant ventricular arrhythmia including ventricular tachycardia,
                  ventricular fibrillation, history of cardiac arrest, atrioventricular block
                  (Mobitz II or III), use of cardiostimulator

               -  QTc interval &gt; 450 ms in men or 470 ms in women (ECG) (calculated according to
                  Fredericia formula), or a diagnosis of long QT syndrome

               -  Hypotension (systolic blood pressure &lt; 86 mm Hg or bradycardia with a heart rate
                  of &lt; 50 beats per minute (ECG) except when caused by medications (e.g.
                  beta-blockers).

               -  Uncontrolled arterial hypertension (systolic arterial pressure &gt; 170 millimeters
                  of mercury or diastolic blood pressure &gt; 105 millimeters of mercury)

         12. Pregnancy and lactation

         13. Presence of HIV antibodies, Hepatitis В and С antibodies

         14. Drug or alcohol abuse at the moment of screening or in the past which according to the
             opinion of the Investigator makes the patient unsuitable for participation in the
             study

         15. Significant allergic reactions in medical history

         16. Participation in other clinical studies or administration of test drugs during 30 days
             before beginning of the study or persisting side effect of any of the test drugs;

         17. Toxic effects of previous treatments or complications after surgical treatments that
             did not resolve to grades 1 and/or 0 (according to the CTCAE scale).

         18. Patient not willing to participate in the study or unable to understand or follow the
             protocol instructions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey Tjulandin, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Russian Oncological Research Center n.a. N. N. Blokhin RAMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Russian Oncological Research Center n.a. N. N. Blokhin RAMS</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Stavropol Territory &quot;Pyatigorsk oncology dispensary&quot;</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Peterburg State Budgetary healthcare Institution &quot;City Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioEq LLC</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197342</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Institution of healthcare &quot;Saint-Petersburg clinical research and practical centre of specialized medical aid (oncology)&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution of Yaroslavl region &quot;Regional Clinical oncology hospital&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Final results will be published</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

